Regarding the use of medications inherent to the treatment ofend-stage CKD, there is a reduction in the use of erythropoietin, iron andcalcitriol and an increase in the use of paricalcitol, cinacalcet and sevelamer(Figure 7). This evidence concerns the gene EPO and chronic kidney disease.